Q2 Earnings Estimate for CAPR Issued By HC Wainwright

Capricor Therapeutics Inc (NASDAQ:CAPR) – HC Wainwright issued their Q2 2025 earnings estimates for Capricor Therapeutics in a report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings of ($0.36) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $77.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $11.13 million for the quarter, compared to the consensus estimate of $9.87 million.

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

CAPR stock opened at $12.86 on Friday. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The company’s fifty day moving average price is $14.06 and its 200-day moving average price is $14.62. The company has a market capitalization of $584.74 million, a PE ratio of -12.13 and a beta of 4.10.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CAPR. Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after purchasing an additional 700,243 shares during the last quarter. Farallon Capital Management LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth about $31,056,000. Geode Capital Management LLC grew its holdings in shares of Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares during the last quarter. Altium Capital Management LLC grew its holdings in shares of Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after purchasing an additional 429,000 shares during the last quarter. Finally, Woodline Partners LP bought a new position in shares of Capricor Therapeutics in the fourth quarter worth about $8,693,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.